Bafna Pharma gets UK MHRA approval for Paracetamol and Loperamide

Bafna Pharmaceuticals, (BSE Code: 532989) Chennai-based pharma company engaged in the business of manufacturing of pharmaceutical formulations of Betalactum and Non–Betalactum received approval from Medicines and Healthcare products Regulatory Agency of the UK (UK MHRA) for manufacturing Paracetamol Tablets and Loperamide capsules . This is the eighth formulation approval received from UK MHRA for a product by Bafna Pharma for contract manufacturing.

Commenting on UK MHRA approval Mr. Mahaveer Chand Bafna, Chairman and MD of Bafna Pharmaceuticals Ltd. says, “The approval from UK MHRA for Paracetamol and Loperamide would further help us strengthen our already expanding business in the European market. UK MHRA approval will enable Bafna Pharma to widen the customer base in Europe. Following the recent launch of our FR&D facility in Chennai, we will be filing dossiers for the ever growing UK and the European Markets.”

The UK- MHRA has granted Bafna Pharma the approval for manufacturing Paracetamol Tablets 500mg & Paracetamol Caplets 500 mg. These tablets are used in the treatment of mild to moderate pain including headache, toothache, period pains, symptomatic relief of influenza, feverish colds and rheumatic aches and pains. The active ingredient, Paracetamol is a centrally acting analgesic (a pain killer that acts on pain centres in the brain), which is used to relieve pain in the body.

Similarly, Loperamide 2mg Capsules is used for the treatment of symptoms of sudden, short-term diarrhoea (acute diarrhoea) in adults and children over 12 years. Loperamide 2mg Capsules contain the active ingredient loperamide hydrochloride which belongs to a group of medicines called antidiarrhoeals which is a synthetic opioid that inhibits gut motility by binding to opiate receptors in the gut wall and may also reduce gastrointestinal secretions, resulting in improvement in the diarrhoea symptoms.

About Bafna Pharmaceuticals Ltd:
The company has over 73 products registered in Sri Lanka, Ukarine, Lao and Ghana. The company has two manufacturing facilities. A WHO-GMP certified manufacturing facility in Madhavaram, which is a 100 percent Export oriented Unit (EOU) and an EU GMP facility at Grantlayan, Chennai. Recently the company received the Good Manufacturing Practices (GMP) approval from Ethiopia’s Drug Administration and Control Authority (DACA) for its non-betalactam facility.

The company in the month of April 2010 inaugurated its Research and Development (Formulation) (FR&D) facility, a pilot plant in Chennai. The company has secured ISO 9001: 2008 Certificate of Registration for Manufacture and Export of Pharmaceutical products. Bafna Pharma has also received EU GMP Compliances from (MHRA) Medicines and Healthcare products Regulatory Agency, U.K. This accreditation has made Bafna Pharmaceuticals the 35th facility to achieve this key recognition in India and has opened the gates for exploring markets of European Union.